The influence of thermal treatment and type of insoluble poly(meth)acrylates on dissolution behavior of very soluble drug from hypromellose matrix tablets evaluated by multivariate data analysis
Language English Country England, Great Britain Media print-electronic
Document type Journal Article
- Keywords
- Eudragit® NE, HPMC, NM, Prolonged drug release, RL, RS, burst effect, levetiracetam, matrix tablets, multivariate data analysis, thermal treatment,
- MeSH
- Anticonvulsants administration & dosage chemistry MeSH
- Cellulose chemistry MeSH
- Hypromellose Derivatives chemistry MeSH
- Polymethacrylic Acids chemistry MeSH
- Delayed-Action Preparations chemistry MeSH
- Levetiracetam MeSH
- Multivariate Analysis MeSH
- Piracetam administration & dosage analogs & derivatives chemistry MeSH
- Drug Compounding methods MeSH
- Solubility MeSH
- Tablets MeSH
- Temperature MeSH
- Drug Liberation MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anticonvulsants MeSH
- Cellulose MeSH
- Hypromellose Derivatives MeSH
- Polymethacrylic Acids MeSH
- Delayed-Action Preparations MeSH
- Levetiracetam MeSH
- methylmethacrylate-methacrylic acid copolymer MeSH Browser
- microcrystalline cellulose MeSH Browser
- Piracetam MeSH
- Tablets MeSH
Hypromellose matrices exhibit extended burst effect immediately after contact with aqueous medium, especially when a water-soluble drug is incorporated. The objective of this study was to reduce burst effect and maintain complete dissolution of a very soluble levetiracetam over 12 h period from hypromellose K4M matrices to obtain zero-order kinetics. Desired changes were achieved by applying water dispersions of insoluble Eudragits® (NE, NM, RL, RS) as a granulation liquid to the drug/microcrystalline cellulose mixture during high-shear granulation (non-thermal treated set) and consequently by thermally treating granules or final tablets (TT), respectively. Applying Eudragit® water dispersions to the drug/microcrystalline cellulose mixture was recognized as an effective method of significantly reducing the burst release (25.4-33.7%) of levetiracetam in comparison with a reference sample without Eudragit®. Multivariate data analysis showed that the addition of Eudragit® reduced burst effect, increased fitting with zero-order kinetics, and supported matrix erosion as the supplementary mechanism to predominant diffusion. Moreover, resulting PCA sub-model revealed the addition of Eudragit® RL and thermal treatment of tablets to be the most suitable method of all. For a 12 h dissolution profile, characterized by low burst effect and drug release close to 100% at the 12th hour, sample RL_TT was the most suitable.
References provided by Crossref.org